Table 1.

Summary of ICI-induced exclusively cutaneous SLRs

Sex/age	Primary disease	Agent	Onset after initiation of ICI (doses)	Clinical presentation	Management of SLR	Outcome of SLR	Study
F/60	Lung adenocarcinoma	Ipilimumab+nivolumab	7 months (3 doses ipilimumab, 10 doses nivolumab)	1–4 mm pink papules, some coalescing into plaques on posterior neck, upper arms and malar cheeks	Topical corticosteroids	Improvement but not resolution	Suozzi et al17
F/63	Lung adenocarcinoma	Nivolumab	3.5 months (7 doses)	2–6 mm scaly, erythematous papules coalescing into plaques on bilateral periorbital area and posterior neck, progressing to red-brown plaques involving glabella and nasal bridge	No improvement with TCS, ICI held for 1 cycle, systemic corticosteroids, hydroxychloroquine	Resolution	Birnbaum et al18
F/57	Ovarian carcinoma	Ipilimumab+nivolumab	10 months	1–3 cm tender, subcutaneous nodules on lower extremities, forearm and hip	D/c ICI	Resolved	Tetzlaff et al19
F/39	Melanoma	Nivolumab	3 months (6 doses)	Painful subcutaneous nodules on bilateral lower extremities and buttocks	D/c ICI, systemic steroids, hydroxychloroquine	Resolution	Tetzlaff et al19
F/56	Melanoma	Nivolumab	4+ months	FDG-avid subcutaneous nodules	Excision	Not reported	Ogawa et al20
M/72	Melanoma	Pembrolizumab	22 months	Subcutaneous nodules	None	Not resolved	Dimitriou et al21
M/64	Melanoma	Pembrolizumab	2 months	2 mm pigmented nodule on right submandibular area	None	Not reported	Woodbeck et al22
M/67	Melanoma	Ipilimumab	2 years	Coalescent papular lesions on back, face, arms, legs, hands, feet, groin and hips	D/c ICI, systemic, intramuscular and topical corticosteroids	Resolved	Cervantes et al23
F/49	Renal cell carcinoma	Ipilimumab+nivolumab	1 month (1 dose)	Subcutaneous nodules on left forearm and elbow	D/c ICI	Improving	Mobini et al7
M/58	Melanoma	Ipilimumab	1 month	Erythematous, scaly tender papules, plaques and nodules on black tattooed areas on chest, shoulders, upper back, left forearm and right thigh	D/c ICI, topical, intramuscular and systemic corticosteroids	Improving	Mobini et al7
M/57	Melanoma	Nivolumab or ipilimumab+nivolumab	1.3 months	Cutaneous lesions	Not reported, ICI continued	Resolved	Chorti et al24
M/36	Melanoma	Nivolumab (exacerbated by addition of BRAF‐inhibitor)	19 months	Micropapules in axilla and inguinal crease	Hydroxychloroquine, D/c BRAF‐inhibitor	Resolved	Pham et al15
F/70	Breast adenocarcinoma	Pembrolizumab	1 month	Shiny, pink to brown patches and plaques on the face, flat-topped, red-brown to violaceous indurated papules on dorsal upper extremities	Topical corticosteroids, topical calcineurin inhibitors	Improving	Current study

D/c, discontinue; F, female; ICI, immune checkpoint inhibitor; M, male; SLRs, sarcoid-like reactions; TCS, topical corticosteroids.